Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 15:59:30 04/07/2024 BST			5-day change	1st Jan Change
970 ^DKK	+0.26%		-3.25%	+38.95%

05:13pm	ETF of the week: Investing in strong trends with the momentum theme
02:53pm	NOVO NORDISK : Deutsche Bank remains its Buy rating	ZD

NOVO NORDISK : Jefferies reiterates its Sell rating

July 02, 2024 at 12:38 pm

Jefferies's analyst Peter Welford maintains his Sell rating on the stock. The target price is increased from DKK 530 to DKK 575.

Latest news about Novo Nordisk A/S

ETF of the week: Investing in strong trends with the momentum theme	04:13pm
NOVO NORDISK : Deutsche Bank remains its Buy rating	01:53pm	ZD
AlphaValue/Baader Europe Upgrades Novo Nordisk to Buy from Add, Lifts PT	12:44pm	MT
Sector Update: Health Care Stocks Fall in Afternoon Trading	07-03	MT
Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows	07-03	MT
Top Midday Stories: Southwest Board Approves Shareholder Rights Plan; National Amusements Agrees to Preliminary Deal to Sell Paramount to Skydance; Ozempic, Wegovy Linked to Blinding Eye Condition, Study Says	07-03	MT
Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows	07-03	MT
Global markets live: Eli Lilly, Apple, Walmart, Shell, Rio Tinto...	07-03
Wegovy, Ozempic linked with sight-threatening eye disorder in study	07-03	RE
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	07-03	MT
Ozempic, Wegovy Linked to Higher Risk of Blinding Eye Condition, Study Says	07-03	MT
NOVO NORDISK : Berenberg reiterates its Neutral rating	07-03	ZD
NOVO NORDISK : Buy rating from Goldman Sachs	07-03	ZD
US President Calls Out Eli Lilly, Novo Nordisk Over High Drug Prices	07-03	MT
US President Calls Out Eli Lilly, Novo Nordisk Over High Drug Prices	07-03	MT
Tesla, megacaps drive S&P 500, Nasdaq higher; rates outlook in focus	07-02	RE
Novo Nordisk, Eli Lilly Charging 'Unconscionably' High Prices, Biden, Sanders Say	07-02	MT
Top Midday Stories: Tesla, GM Report Vehicle Deliveries; Biden, Sanders Say Novo Nordisk, Eli Lilly Charge 'Unconscionably' High Prices; Warner Bros. Interested in Deal With Paramount	07-02	MT
US President Calls Out Eli Lilly, Novo Nordisk Over High Drug Prices	07-02	MT
Wall St edges lower as Powell signals caution; Tesla jumps after delivery data	07-02	RE
US FDA warns website over unlawful sale of weight-loss drugs	07-02	RE
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	07-02	MT
Wall St set for lower open as megacaps retreat with jobs data, Powell in focus	07-02	RE
Novo Nordisk, Eli Lilly Charging 'Unconscionably' High Prices, Biden, Sanders Say	07-02	MT
Biden says Novo Nordisk must cut prices of diabetes, weight loss drugs	07-02	RE

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Novo Nordisk CEO: Demand for Wegovy outstrips supply

May 02, 2024 at 05:36 pm

NOVO NORDISK : Q1 beat; guidance upgrade but sentiment nonetheless dampened by price reductions

May 02, 2024 at 05:09 pm

Novo Nordisk doesn't disappoint

January 31, 2024 at 03:48 pm

More Strategies

Ratings for Novo Nordisk A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

967.5 DKK

Average target price

952.2 DKK

Spread / Average Target

-1.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+38.95%	621B
ELI LILLY AND COMPANY	+54.07%	809B
JOHNSON & JOHNSON	-7.05%	351B
MERCK & CO., INC.	+15.44%	319B
ABBVIE INC.	+5.72%	289B
ASTRAZENECA PLC	+14.40%	238B
ROCHE HOLDING AG	-0.53%	221B
NOVARTIS AG	+14.65%	218B
AMGEN INC.	+7.42%	166B
PFIZER, INC.	-3.79%	157B

Other Pharmaceuticals

Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

NOVO NORDISK : Jefferies reiterates its Sell rating

Latest news about Novo Nordisk A/S

Chart Novo Nordisk A/S

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novo Nordisk A/S

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals